

BiblioGETNE

Nº11 - diciembre 2023

ÍNDICE:

GETNE ACADEMY

NETTER-2 / NABNEC / Pósters

Post-ASCOGI24

GETNE ACADEMY

Jorge Hernando Cubero (H.U. Vall d'Hebron, Barcelona)

Nieves Martínez Lago (Complejo H.U. de Ferrol)

Contenido

- NETTER-2
- NABNEC
- Pósters


NETTER-2

- Estudio fase III comparando 177Lu-DOTATATE x4 + Octreotido LAR 30/28d vs Octreotido Lar 60/28d.
- Pacientes con TNE GEP G2 (Ki67 >10%) y G3 bien diferenciados.
- N = 226

- PFS 22.8 vs 8.5 meses.
- ORR 43% vs 9.3%

- **Comentario:** estudio importante que explora la eficacia del tratamiento con PRRT en una población con tumores más agresivos que el estudio NETTER-1. El tratamiento con 177Lu-DOTATATE se posiciona como una opción en líneas tempranas en esta población de pacientes, aunque resulta fundamental la individualización de la mejor primera línea y secuencia terapéutica en cada caso. A destacar también los resultados del brazo control con una PFS de 8.5 meses y ORR 9.3% en una población que tradicionalmente no se ha tratado con análogos de somatostatina.

¹⁷⁷Lu-DOTATATE showed significant improvement in primary PFS endpoint



Number at risk	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36
¹⁷⁷ Lu-DOTATATE	151	143	138	129	125	104	92	80	68	53	41	37	23	19	13	9	4	2	0
High dose octreotide	75	67	49	42	37	24	21	16	16	10	5	5	4	1	1	0	0	0	0

PFS centrally assessed according to RECIST 1.1
 CI, confidence interval; HR, hazard ratio; NE, not estimable; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors.

	¹⁷⁷ Lu-DOTATATE arm n=151	High dose octreotide arm n=75
PFS median, months (95% CI)	22.8 (19.4, NE)	8.5 (7.7, 13.8)
Stratified HR (95% CI)	0.276 (0.182, 0.418)	
p-value	<0.0001	
Number of events, n (%)		
Progression	55 (36)	46 (61)
Death	47 (31)	41 (55)
	8 (5)	5 (7)

72% reduction in the risk of disease progression or death in the ¹⁷⁷Lu-DOTATATE arm versus the high dose octreotide arm

NABNEC

- Estudio fase II no comparativo que evalúa la actividad de nab-paclitaxel en pacientes con G3 GI-NEN.
- Brazo A: Nab-Paclitaxel + Carboplatino.
- Brazo B: Carboplatino + Etopósido.
- Pacientes con carcinoma neuroendocrino de origen gastrointestinal.
- N = 46

- ORR 53% (Brazo A), 42% (Brazo B)
- PFS a 12 meses 8% (Brazo A), 21% (Brazo B)

- **Comentario:** el estudio alcanza su objetivo primario (ORR) y el tratamiento con carboplatino + nab-paclitaxel demuestra actividad en NEC GI. Todavía es necesario explorar el papel de nab-paclitaxel en un futuro estudio fase III.

The NABNEC trial met its primary endpoint

RR was 53% (38-69%) in the experimental arm and 42% (16-71%) in the control group

Best response and objective tumour response defined according to RECIST v1.1 criteria as a complete response (CR) or a partial response (PR) by group. 95% confidence interval is shown next to the proportion

	Control (carbo/etop), N = 12 (95% CI)	Exp (carbo/nab-pac) Rand phase, N = 21 (95% CI)	Exp Single arm phase, N = 22 (95% CI)	Exp (Rand+Single) phase, N = 43 (95% CI)
Best Response				
CR - Complete Response	0 (0%) (0.00%, 30%)	2 (9.5%) (1.7%, 32%)	1 (4.5%) (0.24%, 25%)	3 (7.0%) (1.8%, 20%)
PD - Progressive Disease	4 (33%) (11%, 65%)	3 (14%) (3.8%, 37%)	5 (23%) (8.7%, 46%)	8 (19%) (8.9%, 34%)
PR - Partial Response	5 (42%) (16%, 71%)	8 (38%) (19%, 61%)	12 (55%) (33%, 75%)	20 (47%) (31%, 62%)
SD - Stable Disease	3 (25%) (6.7%, 57%)	8 (38%) (19%, 61%)	4 (18%) (6.0%, 41%)	12 (28%) (16%, 44%)
Objective Tumour Response Rate				
CR/PR	5 (42%) (16%, 71%)	10 (48%) (26%, 70%)	13 (59%) (37%, 79%)	23 (53%) (38%, 69%)
not CR/PR	7 (58%) (29%, 84%)	11 (52%) (30%, 74%)	9 (41%) (21%, 63%)	20 (47%) (31%, 62%)
n (%), CI = Confidence Interval. Patients that have died or have an unknown response were removed.				

PÓSTERS

- **A640** - Risk of second cancers in long term survivors of NET of the large intestine.
- **A289** - Potential biomarkers for treatment response in advanced non-pancreatic NET.
- **A283** - Prognostic value of MGM status in pancreatic NET treated with CAPTEM.
- **A635** - Assessment of hematological toxicity in patients with advanced NET and extensive/innumerable bone metastases undergoing Lu177-DOTATATE treatment.
- **A194** - Prognostic factors for OS in advanced digestive NEC patients treated with first line Cisplatin-based chemotherapy: A post hoc análisis of JCOG1213.
- **A178** - Real-world 177Lu-DOTATATE PRRT: Treatment outcomes with dosing variations and in non-midgut NET.

Secretaría Técnica GETNE

MFAR Barcelona

Balmes 243, Escalera A 5^ª1^ª

08006 Barcelona

Teléfono: +34 93 434 44 12

Persona de contacto:

María Montero 690 127 772

getne.academy@getne.org

getne@getne.org



www.getne.org

 **@GrupoGetne**